Review Papers Claim by Claim

Core results (paper‑sourced)

• Prospective cohort: 29 antibody‑positive participants followed to T3 (~27 ±1 weeks); binding antibodies measured at ~7, 14 and 27 weeks; neutralization measured at T3 Methods summary
• At 6 months all 29 had neutralizing antibodies (median titer 1:64, range 1:16–1:256); RBD pan‑Ig remained positive in all; two participants were below S1‑IgG cut‑off at 6 months but retained neutralization Primary results
• High assay concordance: 163/167 paired results concordant; Cohen's kappa = 0.950 Assay performance

Strengths

• Prospective longitudinal sampling to 6 months with paired binding and neutralization data in the same individuals Prospective design
• Use of two complementary binding assays (RBD pan‑Ig sandwich vs S1‑IgG direct) and a pseudovirus neutralization assay validated against live virus, improving internal validity Assay details

Limitations and critical caveats

1. Small sample and limited demographics: only 29 antibody‑positive participants followed, mostly healthy adults age 29–65 with mostly mild–moderate disease — reduces precision and external generalizability to children, elderly, or immunocompromised patients Limitations noted
2. Missing raw individual‑level data: only summary statistics and figures provided; no public dataset or per‑participant numeric table included, which hampers reproducibility and pooling with other cohorts (meta‑analysis) Data availability
3. Assay heterogeneity and cut‑off recalculation: Euroimmun control reagents had high interassay CV and the authors recalculated an S1 cutoff from 122 negatives (mean+3SD), which complicates direct comparison to other studies using manufacturer cutoffs and may influence reported seronegativity for S1‑IgG in two participants Assay recalibration
4. Outcome measured = serology and in vitro neutralization (pseudovirus): these are reasonable correlates but are not direct clinical correlates of sterilizing protection or long‑term risk of reinfection, especially with evolving variants (study predates major variants) Neutralization vs clinical protection

Interpretation, balanced

The data provide moderate‑strength evidence that after mild–moderate COVID‑19 in mostly healthy adults, antibody responses — particularly RBD‑directed antibodies and neutralizing activity — persist to 6 months. Loss of S1‑IgG in two participants while neutralization and RBD pan‑Ig remained positive highlights assay dependence: RBD assays and functional neutralization correlated better with neutralizing titers than S1‑IgG alone in this cohort Assay correlation finding

What would challenge or overturn the main conclusion?

• Availability of individual raw data showing rapid within‑subject declines in neutralization titer (contrary to reported medians) or more participants with loss of neutralization at 6 months.
• Evidence of reinfections in similarly matched, seropositive individuals with contemporaneous neutralizing titers (i.e., documented immune escape or waning protection despite neutralization present).
• External larger cohorts showing discordant kinetics (e.g., large fraction losing neutralization by 6 months) after standardizing assays.

Recommendations to improve and follow up

1. Share anonymized individual‑level assay results (binding OD/index and neutralizing titers) in a public repository to enable pooling and meta‑analysis.
2. Repeat neutralization testing against later variants of concern (SARS‑CoV‑2 VOCs) when possible to assess breadth of neutralizing activity.
3. Extend follow‑up to 12 months and add cellular immunity (memory B and T cell) assays to assess durability beyond serum antibody titers.

Bottom line

Moderate‑quality prospective evidence that RBD‑directed binding antibodies and functional neutralization persist to 6 months after mostly mild COVID‑19 in healthy adults; small sample, assay heterogeneity and lack of raw data constrain generalizability and reproducibility.

Primary source: Tyrol cohort paper